DOCSLIB.ORG

Human Cytokine Panel, 80 Plex 2012年7月 (Panel #312064 Page 1/2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Cytokine Panel, 80 Plex 2012年7月 (Panel #312064 Page 1/2) QGP2.0 (MAG), Human Cytokine panel, 80 plex 2012年7月 (Panel #312064 Page 1/2) Symbol RefSeq Gene IL10 NM_000572 interleukin 10 IL1A NM_000575 interleukin 1, alpha IL1B NM_000576 interleukin 1, beta IL8 NM_000584 Interleukin 8 IL2 NM_000586 interleukin 2 IL4 NM_000589 interleukin 4 TNF NM_000594 Tumor necrosis factor (TNF superfamily, member 2) IL6 NM_000600 interleukin 6 (interferon, beta 2) IFNG NM_000619 interferon, gamma FASLG NM_000639 tumor necrosis factor (ligand) superfamily, member 6 transforming growth factor, beta 1 (Camurati-Engelmann TGFB1 NM_000660 disease) CSF2 NM_000758 colony stimulating factor 2 (granulocyte-macrophage) IL5 NM_000879 interleukin 5 (colony-stimulating factor, eosinophil) IL7 NM_000880 interleukin 7 interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic IL12A NM_000882 lymphocyte maturation factor 1, p35) PPIB NM_000942 peptidylprolyl isomerase B (cyclophilin B) ACTB NM_001101 actin, beta IL18 NM_001562 interleukin 18 (interferon-gamma-inducing factor) GAPDH NM_002046 glyceraldehyde-3-phosphate dehydrogenase IFNB1 NM_002176 interferon, beta 1, fibroblast interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic IL12B NM_002187 lymphocyte maturation factor 2, p40) IL13 NM_002188 interleukin 13 interleukin 17 (cytotoxic T-lymphocyte-associated serine IL17A NM_002190 esterase 8) LTB NM_002341 lymphotoxin beta (TNF superfamily, member 3) IL22 NM_020525 interleukin 22 IL21 NM_021803 interleukin 21 IL15 NM_172174 interleukin 15 LTA NM_000595 lymphotoxin alpha (TNF superfamily, member 1) TGFB3 NM_003239 transforming growth factor, beta 3 CD70 NM_001252 tumor necrosis factor (ligand) superfamily, member 7 c-fos induced growth factor (vascular endothelial growth factor FIGF NM_004469 D) IFNA1 NM_024013 interferon, alpha 1 INHBA NM_002192 inhibin, beta A (activin A, activin AB alpha polypeptide) IL9 NM_000590 interleukin 9 IL20 NM_018724 interleukin 20 IL24 NM_006850 interleukin 24 TGFB2 NM_003238 Transforming growth factor, beta 2 BMP4 NM_001202 bone morphogenetic protein 4 MSTN NM_005259 growth differentiation factor 8 GDF11 NM_005811 growth differentiation factor 11 GDF3 NM_020634 growth differentiation factor 3 tumor necrosis factor receptor superfamily, member 11b TNFRSF11B NM_002546 (osteoprotegerin) TGFA NM_003236 transforming growth factor, alpha IFNA2 NM_000605 interferon, alpha 2 IL16 NM_004513 interleukin 16 (lymphocyte chemoattractant factor) IL25 NM_022789 interleukin 17E TNFSF11 NM_003701 tumor necrosis factor (ligand) superfamily, member 11 TNFSF10 NM_003810 tumor necrosis factor (ligand) superfamily, member 10 IL3 NM_000588 interleukin 3 (colony-stimulating factor, multiple) IL36G NM_019618 interleukin 1 family, member 9 BMP2 NM_001200 bone morphogenetic protein 2 BMP5 NM_021073 bone morphogenetic protein 5 BMP6 NM_001718 bone morphogenetic protein 6 NODAL NM_018055 nodal homolog (mouse) TNFSF13B NM_006573 tumor necrosis factor (ligand) superfamily, member 13b QGP2.0 (MAG), Human Cytokine panel, 80 plex 2012年7月 (Panel #312064 Page 2/2) Symbol RefSeq Gene BMP7 NM_001719 bone morphogenetic protein 7 (osteogenic protein 1) TNFSF13 NM_003808 tumor necrosis factor (ligand) superfamily, member 13 IFNK NM_020124 Interferon, kappa CSF1 NM_000757 colony stimulating factor 1 (macrophage) PDGFA NM_002607 Platelet-derived growth factor alpha polypeptide IFNA5 NM_002169 interferon, alpha 5 IL37 NM_014439 interleukin 1 family, member 7 (zeta) TXLNA NM_175852 taxilin TNFSF14 NM_003807 tumor necrosis factor (ligand) superfamily, member 14 BMP8B NM_001720 bone morphogenetic protein 8b (osteogenic protein 2) growth differentiation factor 5 (cartilage-derived morphogenetic GDF5 NM_000557 protein-1) FAM3B NM_058186 family with sequence similarity 3, member B tumor necrosis factor (ligand) superfamily, member 4 (tax- TNFSF4 NM_003326 transcriptionally activated glycoprotein 1, 34kDa) IL1F10 NM_032556 Interleukin 1 family, member 10 (theta) IL36B NM_014438 interleukin 1 family, member 8 (eta) BMP3 NM_001201 bone morphogenetic protein 3 (osteogenic) GDF10 NM_004962 growth differentiation factor 10 IL19 NM_013371 interleukin 19 TNFSF12 NM_003809 tumor necrosis factor (ligand) superfamily, member 12 IL36RN NM_012275 interleukin 1 family, member 5 (delta) GDF2 NM_016204 growth differentiation factor 2 IFNA8 NM_002170 interferon, alpha 8 IL36A NM_014440 interleukin 1 family, member 6 (epsilon) BMP1 NM_001199 bone morphogenetic protein 1 GDF9 NM_005260 growth differentiation factor 9.
Load more

Recommended publications
  • Data Sheet Huil36g (152 A.A.)
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36G is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Human IL36G (152 a.a.) shares 58%, 59%, 68% and 69% amino acid sequence identity with mouse, rat, bovine and equine IL36G, respectively, and 23-57% amino acid sequence identity with other family members. Catalog Number 1110-36F Product Name IL36G (IL-36 gamma), Human (152 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW ~17.0 kDa (152 amino acids) Sequence SMCKPITGTI NDLNQQVWTL QGQNLVAVPR SDSVTPVTVA VITCKYPEAL EQGRGDPIYL GIQNPEMCLY CEKVGEQPTL QLKEQKIMDL YGQPEPVKPF LFYRAKTGRT STLESVAFPD WFIASSKRDQ PIILTSELGK SYNTAFELNI ND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The ED50 as determined by its ability to induce IL-8 secretion by human preadipocytes is less than 10 ng/ml, corresponding to a specific activity of >1 × 105 IU/mg.
    [Show full text]
  • Human Vδ2 T Cells Are a Major Source of Interleukin-9
    Human Vδ2 T cells are a major source of interleukin-9 Christian Petersa, Robert Häslerb, Daniela Wescha, and Dieter Kabelitza,1 aInstitute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany; and bInstitute of Clinical Molecular Biology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany Edited by Willi K. Born, National Jewish Health, Denver, CO, and accepted by Editorial Board Member Philippa Marrack September 12, 2016 (received for review May 13, 2016) Vδ2Vγ9 T cells are the dominant γδ T-cell subset in human periph- Vδ2 T cells produce different cytokines, can be converted into + eral blood. Vδ2 T cells recognize pyrophosphate molecules derived forkhead box protein P3 (FoxP3) regulatory cells (20, 21), and from microbes or tumor cells; hence, they play a role in antimicro- may acquire professional antigen-presenting capacity (22). Depend- bial and antitumor immunity. TGF-β, together with IL-15, induces ing on priming conditions, Vδ2 T cells can secrete IFN-γ,IL-4,IL- a regulatory phenotype in Vδ2 T cells, characterized by forkhead 17, and IL-22, and thus recapitulate cytokine patterns of well-defined box protein P3 (FoxP3) expression and suppressive activity on CD4 functional Th subsets (23, 24). T-cell activation. We performed a genome-wide transcriptome Here, we identified peripheral blood Vδ2Tcellsasamajorsource analysis and found that the same conditions (TGF-β plus IL-15) of IL-9. In the presence of TGF-β and IL-15 but the absence of IL-4, strongly enhanced the expression of additional genes in Vδ2T high levels of IL-9 were secreted already 4 d after initial in vitro ac- cells, including IKAROS family zinc finger 4 (IKZF4; Eos), integrin tivation.
    [Show full text]
  • Interleukin-10 Family and Tuberculosis: an Old Story Renewed Abualgasim Elgaili Abdalla1, 2, Nzungize Lambert1, Xiangke Duan1, Jianping Xie1
    Int. J. Biol. Sci. 2016, Vol. 12 710 Ivyspring International Publisher International Journal of Biological Sciences 2016; 12(6): 710-717. doi: 10.7150/ijbs.13881 Review Interleukin-10 Family and Tuberculosis: An Old Story Renewed Abualgasim Elgaili Abdalla1, 2, Nzungize Lambert1, Xiangke Duan1, Jianping Xie1 1. Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Beibei, Chongqing 400715, China. 2. Department of Clinical Microbiology, College of Medical Laboratory Sciences, Omdurman Islamic University, Omdurman, Khartoum, Sudan. Corresponding author: Jianping Xie E-mail: [email protected] Tel&Fax: 862368367108. © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. Received: 2015.09.17; Accepted: 2016.01.15; Published: 2016.04.27 Abstract The interleukin-10 (IL-10) family of cytokines consists of six immune mediators, namely IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26. IL-10, IL-22, IL-24 and IL-26 are critical for the regulation of host defense against Mycobacterium tuberculosis infections. Specifically, IL-10 and IL-26 can suppress the antimycobacterial immunity and promote the survival of pathogen, while IL-22 and IL-24 can generate protective responses and inhibit the intracellular growth of pathogen. Knowledge about the new players in tuberculosis immunology, namely IL-10 family, can inform novel immunity-based countermeasures and host directed therapies against tuberculosis.
    [Show full text]
  • Huil36g 169 Data Sheet
    Growth Factor Data Sheet GoldBio growth factors are manufactured for RESEARCH USE ONLY and cannot be sold for human consumption! Interleukin-36G (IL36G) is a pro-inflammatory cytokine that plays an important role in the pathophysiology of several diseases. IL36A, IL36B and IL36G; (formerly IL1F6, IL1F8, and IL1F9) are IL1 family members that signal through the IL1 receptor family members IL1Rrp2 (IL1RL2) and IL1RAcP. IL36B is secreted when transfected into 293-T cells and could constitute part of an independent signaling system analogous to that of IL1A and IL1B receptor agonist and interleukin-1 receptor type I (IL1R1). Furthermore, IL36G also can function as an agonist of NFκB activation through the orphan IL1- receptor-related protein 2. Recombinant human IL36G is synthesized as a protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site.There is a 53% amino acid homology between human and mouse IL36G. IL36G also has a 25-55% amino acid homology with IL36G and IL1RN, IL1B, IL36RN, IL36A, IL37, IL36B and IL1F10. Catalog Number 1110-36E Product Name IL36G (IL-36 gamma), Human (169 a.a.) Recombinant Human Interleukin-36γ IL36G, IL36γ Interleukin 1 Homolog 1 (IL1H1) Interleukin 1-Related Protein 2 (IL1RP2) Interleukin 1 Family, Member 9 (IL1F9) Source Escherichia coli MW 18.7 kDa (169 amino acids) Sequence MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND Accession Number Q9NZH8 Purity >95% by SDS-PAGE and HPLC analyses Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA.
    [Show full text]
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal
    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,766,866 Center Et Al
    USOO5766866A United States Patent (19) 11 Patent Number: 5,766,866 Center et al. 45) Date of Patent: Jun. 16, 1998 54 LYMPHOCYTE CHEMOATTRACTANT Center, et al. The Journal of Immunology. 128:2563-2568 FACTOR AND USES THEREOF (1982). 75 Inventors: David M. Center. Wellesley Hills; Cruikshank, et al. The Journal of Immunology, William W. Cruikshank. Westford; 138:3817-3823 (1987). Hardy Kornfeld, Brighton, all of Mass. Cruikshank, et al., The Journal of Immunology, 73) Assignee: Research Corporation Technologies, 146:2928-2934 (1991). Inc., Tucson, Ariz. Cruikshank, et al., EMBL Database. Accession No. M90301 (21) Appl. No.: 580,680 (1992). 22 Filed: Dec. 29, 1995 Cruikshank. et al. The Journal of Immunology, 128:2569-2574 (1982). Related U.S. Application Data Rand, et al., J. Exp. Med., 173:1521-1528 (1991). 60 Division of Ser. No. 480,156, Jun. 7, 1995, which is a continuation-in-part of Ser. No. 354,961, Dec. 13, 1994, Harlow (1988) Antibodies, a laboratory manual. Cold Spring which is a continuation of Ser. No. 68,949, May 21, 1993, Harbor Laboratory, 285, 287. abandoned. Waldman (1991) Science. vol. 252, 1657-1662. (51) Int. Cl. ....................... G01N 33/53; CO7K 1700; CO7K 16/00: A61K 45/05 Hams et al. (1993) TIBTECH Feb. 1993 vol. 111, 42-44. 52 U.S. Cl. ......................... 424/7.24; 435/7.1; 435/7.92: 435/975; 530/350:530/351; 530/387.1: Center, et al. (Feb. 1995) "The Lymphocyte Chemoattractant 530/388.23: 530/389.2: 424/85.1: 424/130.1 Factor”. J. Lab. Clin. Med. 125(2):167-172.
    [Show full text]
  • LIGHT Is Expressed in Foam Cells and Involved in Destabilization of Atherosclerotic Plaques Through Induction of Matrix Metalloproteinase-9 and IL-8
    LIGHT is Expressed in Foam Cells and Involved in Destabilization of Atherosclerotic Plaques through Induction of Matrix Metalloproteinase-9 and IL-8 Won-Jung Kim and Won-Ha Lee Department of Genetic Engineering, Kyungpook National University, Daegu, Korea ABSTRACT Background: LIGHT (TNFSF14) is a member of tumor necrosis factor superfamily and is the ligand for TR2 (TNFRSF14/HVEM). LIGHT is known to have pro- inflammatory roles in atherosclerosis. Methods: To find out the expression pattern of LIGHT in atherosclerotic plaques, immunohistochemical analysis was performed on human carotid atherosclerotic plaque specimens. LIGHT induced atherogenic events using human monocytic cell line THP-1 were also investigated. Results: Imm- unohistochemical analysis revealed expression of LIGHT and TR2 in foam cell rich regions in the atherosclerotic plaques. Double immunohistochemical analysis further confirmed the expression of LIGHT in foam cells. Stimulation of THP-1 cells, which express TR2, with either recombinant LIGHT or immobilized anti-TR2 monoclonal antibody induced interleukin-8 and matrix metalloproteinase(MMP)-9. Electrophoretic mobility shift assay demonstrated that LIGHT induces nuclear localization of tran- scription factor, nuclear factor (NF)-κB. LIGHT induced activation of MMP-9 is mediated by NF-κB, since treatment of THP-1 cells with the NF-κB inhibitor PDTC (pyrrolidine dithiocarbamate) completely blocked the activation of MMP-9. Conclusion: These data indicate that LIGHT is expressed in foam cells in atherosclerotic plaques and is involved in atherogenesis through activation of pro-atherogenic cytokine IL-8 and destabilization of plaque by inducing matrix degrading enzyme. (Immune Network 2004;4(2):116-122) Key Words: Atherosclerosis, inflammation, matrix metalloproteinase, LIGHT, TNFSF inflammatory cytokines and matrix metallopro- Introduction teinases, and expression of adhesion molecules and Members of tumor necrosis factor superfamily tissue factor (7,8).
    [Show full text]
  • Genetic Determinants of Circulating Interleukin-1 Receptor Antagonist Levels and Their Association with Glycemic Traits
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Trepo - Institutional Repository of Tampere University GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Marja-Liisa Nuotio Syventävien opintojen kirjallinen työ Tampereen yliopisto Lääketieteen yksikkö Tammikuu 2015 Tampereen yliopisto Lääketieteen yksikkö NUOTIO MARJA-LIISA: GENETIC DETERMINANTS OF CIRCULATING INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS AND THEIR ASSOCIATION WITH GLYCEMIC TRAITS Kirjallinen työ, 57 s. Ohjaaja: professori Mika Kähönen Tammikuu 2015 Avainsanat: sytokiinit, insuliiniresistenssi, tyypin 2 diabetes, tulehdus, glukoosimetabolia, genominlaajuinen assosiaatioanalyysi (GWAS) Tulehdusta välittäviin sytokiineihin kuuluvan interleukiini 1β (IL-1β):n kohonneen systeemisen pitoisuuden on arveltu edesauttavan insuliiniresistenssin kehittymistä ja johtavan haiman β-solujen toimintahäiriöihin. IL-1β:n sisäsyntyisellä vastavaikuttajalla, interleukiini 1 reseptoriantagonistilla (IL-1RA), on puolestaan esitetty olevan suojaava rooli mainittujen fenotyyppien kehittymisessä päinvastaisten vaikutustensa ansiosta. IL-1RA:n suojaavan roolin havainnollistamiseksi työssä Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits tunnistettiin veren IL-1RA- pitoisuuteen assosioituvia geneettisiä variantteja, minkä jälkeen selvitettiin näiden yhteyttä glukoosi- ja insuliinimetaboliaan liittyvien muuttujien-, sekä
    [Show full text]
  • Death of HT29 Adenocarcinoma Cells Induced by TNF Family Receptor Activation Is Caspase-Independent and Displays Features of Both Apoptosis and Necrosis
    Cell Death and Differentiation (2002) 9, 1321 ± 1333 ã 2002 Nature Publishing Group All rights reserved 1350-9047/02 $25.00 www.nature.com/cdd Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis 1 ,1 CA Wilson and JL Browning* Introduction 1 Department of Exploratory Biology, Biogen, 12 Cambridge Center, Cambridge, Receptors in the TNF family can initiate both canonical MA 02142, USA apoptotic and necrotic death events.1 Prototypical apoptosis * Corresponding author: JL Browning, Department of Exploratory Biology, follows activation of the Fas receptor on T cells leading to Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA; caspase activation and a cascade of events eventually Tel: 617 679-3312; Fax: 617 679-2304; E-mail: [email protected] culminating in the various hallmarks of apoptosis.2,3 Yet even Received 7.12.01; revised 26.1.02; accepted 22.7.02 in this familiar case, Fas/FADD can trigger necrosis in T cells 4,5 Edited by B Osborne in the absence of caspase signaling. In the well-studied L929 fibroblast line, Fas activation triggers apoptosis while TNF initiates a necrotic event that is actually enhanced by Abstract caspase inhibition.1 Similarly, TNF signaling in the presence of caspase inhibitors was reported to lead to the necrosis of The HT29 adenocarcinoma is a common model of epithelial NIH3T3 fibroblasts and the myeloid U937 cell line.6 It has cell differentiation and colorectal cancer and its death is an oft- been dogmatic that apoptosis is only initiated by those TNF analyzed response to TNF family receptor signaling.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]